Virtual
May 19–21, 2021

The Forum

The 2021 Virtual World Medical Innovation Forum will focus on the growing impact of gene and cell therapy.

Senior healthcare leaders from all over look to shape and debate the area of gene and cell therapy. Our shared belief: no matter the magnitude of change, responsible healthcare is centered on a shared commitment to collaborative innovation–industry, academia, and practitioners working together to improve patients’ lives.

Virtual | May 19–21, 2021

Gene and cell therapy holds immense potential to advance the quality of patient care, reduce cost, and improve outcomes. Systemic complexity, however, can hinder the translation of breakthroughs to clinical care.

Our collective mission: finding solutions to the ethical, medical, operational, and economic challenges confronting GCT-driven care to ensure that patients, providers, and healthcare organizations benefit as soon as possible.

Who Attends

Pharma
Provider
Venture Captial
Medical Device

Investors

Identify new technologies that offer clinical promise. Get insight from clinicians on the medical, technological, and operational factors that drive clinical success. Calibrate your investment strategy with input from industry leaders.

Industry Leaders

Engage with peers from across the GCT and machine learning ecosystem. Meet other executives, decision-makers, and business leaders from health care, pharma, medical devices, and biotech.

Clinicians and Investigators

The one event where physician and clinician leaders connect with peers across the medical landscape. Attend plenary panels, networking events, and fireside chats to capture insight into how GCT and other data-driven technology is enhancing the care continuum.

Healthcare IT

Identify emerging needs for analytics, storage, data, and other services critical to the success of GCT in health care. Connect with partners and innovators; develop long-term strategy.

Academics

Connect with other PhDs, researchers, engineers, and practitioners developing, testing, and optimizing new applications of GCT and machine learning in health care. Identify clinical, financial, and commercial partners.

Data Scientists

GCT-enabled medicine won’t happen without teams of gifted data scientists. Connect with investigators, industry leaders, IT providers, and others to discuss data challenges and solutions.

Attendees by Industry

0%
Clinician, Investigator, Hospital Staff
0%

Non-Profit and Government

0%

Health Information Technology

0%
Life Sciences and Biotech
0%
Other
0%
Medical Device
0%
Venture/Investment

2020 COVID-19 White Paper

The long-term impacts of COVID-19 on healthcare, society and the economy are only beginning to reveal themselves. More than a thousand experts provide their thoughts on what’s ahead.

We’re pleased to share the following analysis.

The Difference

Why You Need to Be a Part
There are a lot of health conferences out there. But how do you discern what’s a worthy one; what makes the Forum the one you should attend? Let us tell you.

Past Forums

The Forum has hosted many top-tier speakers since its inception. See the past keynoters, as well as access to videos of the panels.

Steering Committee

Nino Chiocca, MD, PhD, Neurosurgeon-in-Chief and Chairman, Neurosurgery, BH; Harvey W. Cushing Professor of Neurosurgery, HMS (2021 Co-Chair)

Susan Slaugenhaupt, PhD, Scientific Director, Mass General Research Institute, MGH; Professor, Neurology, HMS (2021 Co-Chair)

Ravi Thadhani, MD, CAO, Mass General Brigham; Professor of Medicine and Faculty Dean for Academic Programs, HMS (2021 Co-Chair)

Luk Vandenberghe, PhD, Grousbeck Family Chair in Gene Therapy, MEE; Associate Professor, Ophthalmology, HMS (2021 Co-Chair)

Xandra Breakefield, PhD, Geneticist, MGH; Professor, Neurology, HMS

Bob Carter, MD, PhD, Chairman, Department of Neurosurgery, MGH; William and Elizabeth Sweet, Professor of Neurosurgery, HMS

Florian Eichler, MD, Director, Center for Rare Neurological Diseases, MGH; Associate Professor, Neurology, HMS

Jean-Francois Formela, MD, Partner, Atlas Venture

Meredith Fisher, PhD, Partner, Mass General Brigham Ventures

Pat Fortune, PhD, VP, Market Sectors, Mass General Brigham Innovation

Anna Greka, MD, PhD, Associate Professor, Medicine, BH; Associate Professor, Medicine, HMS

Reid Huber, PhD, Partner, Third Rock Ventures

Ole Isacson, MD, PhD, Director, Neuroregeneration Research Institute, McLean; Professor, Neurology and Neuroscience, HMS

J. Keith Joung, MD, PhD, Robert B. Colvin, M.D. Endowed Chair in Pathology & Pathologist, MGH; Professor of Pathology, HMS

Adam Koppel, MD, PhD, Managing Director, Bain Capital Life Sciences

Jeannie Lee, MD, PhD, Molecular Biologist, MGH; Professor of Genetics, HMS

John Lepore, MD, SVP, Head of Research, GlaxoSmithKline

Marcela Maus, MD, PhD, Director, Cellular Immunotherapy, Cancer Center, MGH; Assistant Professor, HMS

Marie McDonnell, MD, Chief, Diabetes Section and Director, Diabetes Program, BH; Lecturer, HMS

Patricia Musolino, MD, PhD, Co-Director Pediatric Cerebrovascular Service, MGH; Assistant of Neurology, HMS

Chandra Ramanathan, PhD, Global Head, Pharma R&D Open Innovation, Bayer

Alfred Sandrock, MD, PhD, EVP, R&D and CMO, Biogen

Bastiano Sanna, PhD, EVP, Chief of Cell & Gene Therapies and VCGT Site Head, Vertex Pharmaceuticals

Christine Seidman, MD, Director, Cardiovascular Genetics Center, BH; Thomas W. Smith Professor of Medicine and Genetics, HMS

the Future of Medicine and AI

May 11–13, 2020 | Boston, MA